Skip to main content
S&P 5007,591.70-0.58%DOW52,064.10-0.60%NASDAQ26,081.72-0.65%BTC$77,840.00+1.10%ETH$2,504.38+3.44%GOLD$4,420.40+0.30%OIL$99.44-2.97%
Smart Investors Daily
WV

NASDAQ · WVE

Wave Life Sciences Ltd.

Healthcare · Biotechnology

$4.67

Down-$0.14 (-2.91%)

Updated Sep 11, 2026, 1:06 PM

SID Score

3.7/10

Composite research score

Smart Money

58/100

Neutral

Market cap
2.75B
P/E ratio
-23.03
Dividend yield
0.00%
52-week range
$4.65 – $14.32
Volume
2.77M
Avg. volume
5.46M

Price performance

WVE price history

1M range · 20 trading sessions · Daily adjusted prices

WVE closed at $4.67 after 20 trading sessions, down 10.19% for the selected period.

Last close
$4.67
Period change
-10.19%
Period low
$4.67
Period high
$5.42
Daily close
View OHLC price history
WVE OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Sep 10, 2026$4.76$4.76$4.63$4.672.77M
Sep 9, 2026$4.86$4.9297$4.76$4.813.25M
Sep 8, 2026$4.86$4.965$4.75$4.913.56M
Sep 4, 2026$4.71$4.885$4.65$4.863.03M
Sep 3, 2026$4.80$4.965$4.645$4.706.16M
Sep 2, 2026$4.95$5.0886$4.66$4.885.48M
Sep 1, 2026$4.85$4.98$4.80$4.973M
Aug 31, 2026$5.06$5.07$4.84$4.903.81M
Aug 28, 2026$5.16$5.22$5.03$5.042.25M
Aug 27, 2026$5.23$5.28$5.04$5.162.95M
Aug 26, 2026$5.26$5.30$5.18$5.232.2M
Aug 25, 2026$5.12$5.345$5.12$5.252.41M
Aug 24, 2026$5.27$5.32$5.115$5.124.56M
Aug 21, 2026$5.30$5.48$5.265$5.292.72M
Aug 20, 2026$5.41$5.47$5.18$5.252.66M
Aug 19, 2026$5.39$5.53$5.35$5.4152.84M
Aug 18, 2026$5.09$5.305$5.07$5.293.5M
Aug 17, 2026$5.35$5.44$5.08$5.093.24M
Aug 14, 2026$5.16$5.42$5.14$5.412.88M
Aug 13, 2026$5.25$5.46$5.17$5.206.06M

Latest WVE news

The latest Smart Investors Daily articles mentioning WVE.

Stock researchCompany · Overview

WVE research

Overview

Company profile and research snapshot.

Company profile

WAVE Life Sciences Ltd is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$29.22
Implied upside
—
Analysts
—
WVE recent ratings
DateFirmRatingTarget
Aug 4, 2026MizuhoOutperform—
Jul 31, 2026B. Riley SecuritiesBuy—
Jul 31, 2026WedbushOutperform—
Jul 31, 2026CitigroupBuy—
May 20, 2026Wells FargoOverweight—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 3, 2026

Wave Life Sciences to Present at Cantor 2026 Global Healthcare Conference

CAMBRIDGE, Mass., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced that Paul Bolno, MD, MBA, President and Chief Executive Officer, is scheduled to participate in an analyst-led fireside chat at the Cantor 2026 Global Healthcare Conference in New York City on Thursday, September 10, 2026 at 9:45 a.m. ET. A live webcast of the present

Yahoo · Aug 7, 2026

Did U.S. Redomiciliation and Mixed 1H 2026 Results Just Shift Wave Life Sciences' (WVE) Investment Narrative?

Wave Life Sciences Ltd. reported second-quarter 2026 results with sales of US$2.27 million versus US$8.70 million a year earlier and a wider net loss of US$69.36 million, while first-half 2026 sales rose to US$40.52 million from US$17.87 million and net loss narrowed slightly to US$95.44 million. The company also completed court and shareholder approvals to shift its corporate domicile from Singapore to the United States, a corporate restructuring that could affect its regulatory framework,...

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By